Mesothelioma.com Resources for Patients and their Families

Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107

Brief Summary

RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about cancer and identify biomarkers related to cancer.

PURPOSE: This laboratory study is looking at biomarkers of angiogenesis and disease in patients with unresectable malignant mesothelioma treated on clinical trial CALGB-30107.

Tracking Information
First Received DateMay 9, 2009
Last Changed DateAugust 7, 2017
Start DateNovember 2005
Actual Primary Completion DateMarch 2006
Primary Outcome Measures

Level of biomarkers, including thrombospondin I, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin (high vs low) [Time Frame: baseline]

Secondary Outcome Measures

Effect of biomarker expression level on overall survival [Time Frame: Up to 10 years]

Descriptive Information
PhaseN/A
Study TypeObservational
Condition
  • Malignant Mesothelioma
Intervention
  • Other: immunoenzyme technique
  • Other: laboratory biomarker analysis
Study Arms / Comparison Groups0 / 1
Detailed Description

OBJECTIVES:

- Determine if elevated levels of thrombospondin I serum levels, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin portend a poor prognosis in patients with unresectable malignant mesothelioma treated with vatalanib on protocol CALGB-30107.

- Determine if elevated levels of thrombospondin I serum levels, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin correlate with response or stable disease in these patients.

OUTLINE: Serum samples previously obtained from patients on protocol CALGB-30107 are tested for levels of thrombospondin I serum, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin using enzyme-linked immunosorbent assays (ELISA).

PROJECTED ACCRUAL: A total of 47 specimens will be accrued for this study.

Recruitment Information
Recruitment StatusActive, not recruiting
Anticipated Enrollment47
GenderAll
Ages18 Years - N/A
Accepts Healthy VolunteersNo
Eligibility Criteria

DISEASE CHARACTERISTICS:

- Diagnosis of malignant mesothelioma

- Unresectable disease

- Must have received treatment with vatalanib on protocol CALGB-30107

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

Administrative Information
NCTIDNCT00898547
Responsible Party,
SponsorAlliance for Clinical Trials in Oncology
Verification DateAugust 2017
Mesothelioma Doctors by State
  • Breaking News
  • Emerging Clinical Trials
  • Delivered within 24 hrs

Yes   No

Mesothelioma Cancer Alliance Blog

FEATURED CONTENT:


RECENT POSTS:

Presumption Laws: What they Mean for Firefighters Facing Cancer

Fighting for Change: Honoring Mesothelioma Victim Bruce Vento’s Legacy

Coping with Seasonal Affective Disorder When You Have Cancer

Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: